employers

A New Approach to Mental Health

By combining a network of world-class providers with a highly innovative care platform, TARA Mind offers the safest and most effective treatment for mental health conditions.

The American Workforce Is In Crisis

Nearly one-third of U.S. adults reported having symptoms of depression and/or anxiety in February 2023

Treatment-resistant depression costs US employers and payors an estimated $29 to 48 Billion a year.

Almost one-third of individuals with Major Depressive Disorder (MDD) have Treatment-Resistant Depression (TRD). For them, traditional antidepressants do not – and will not – work.

TRD, alone, causes employees to miss 35.8 lost workdays a year and results in 30-40% higher employee turnover.

65%

of Americans with a mental health condition want access to novel treatments and believe it should be made readily available to those with TRD, depression, and PTSD

BUT, THERE ARE GLARING SYSTEMIC PROBLEMS

Accessibility

75^% believe that mental health services are inaccessible⁶

At TARA Mind, we are building a premium provider network of vetted clinicians and therapists across the US to deliver Ketamine-Assisted Therapy (KAT) to those struggling with their mental health.

Affordability

56^% of Americans cannot cover a $1,000 emergency⁷

Legal ketamine-assisted treatments are too expensive for the average consumer. Employee benefit plans make Ketamine-Assisted Therapy (KAT) more affordable, removing barriers to health equity, and improving outcomes, at scale, all while driving meaningful cost savings for employers.

Our Approach

TARA Mind’s approach is rooted in science and sound clinical practices. Since our inception, we have maintained a laser-like focus on safety, care quality, and treatment efficacy. That is why we have established The TARA Mind Way™.

A set of standards that providers within the TARA Mind network must follow, The TARA Mind Way™ ensures that clients are receiving the types of wraparound services that our expert clinicians believe are the hallmarks of effective and comprehensive ketamine-assisted treatment.

Footnotes

1 KFF (2023 March 20). Mental Health and Substance Use Fact Sheets.
2 Amos, T., et al., (2018 March). Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a Commercial Claims Database. Journal of Clinical Psychiatry.
3 Zhdanava, M., et al., (2021 March 16). The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States. The Journal of Clinical Psychiatry.
4 Amos, T., et al., (2018 March). Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a Commercial Claims Database. Journal of Clinical Psychiatry.
5 Bartlett, L., (2022, January 18). 65% of Americans with Mental Health Conditions Want Access to Psychedelics. Forbes.
6 Cohen Veterans Network (2018 October 10). America’s Mental Health 2018.
7 Reinicke, C., (2022 January 19). 56% of Americans Can’t Cover a $1,000 Emergency Expense with Savings. CNBC.